Axogen, Inc. (LON:0HKD)
18.24
-0.01 (-0.05%)
At close: Feb 21, 2025
Axogen Revenue
Axogen had revenue of $48.64M USD in the quarter ending September 30, 2024, with 17.86% growth. This brings the company's revenue in the last twelve months to $180.86M, up 18.79% year-over-year. In the year 2023, Axogen had annual revenue of $159.01M with 14.74% growth.
Revenue (ttm)
$180.86M
Revenue Growth
+18.79%
P/S Ratio
n/a
Revenue / Employee
$422.56K
Employees
428
Market Cap
626.63M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
Dec 31, 2019 | 106.71M | 22.78M | 27.13% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Axogen News
- 11 days ago - Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 - GlobeNewsWire
- 6 weeks ago - Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Axogen sees Q4 revenue to be $49.4M - Seeking Alpha
- 6 weeks ago - First Light Asset Management, LLC Increases Stake in Axogen Inc - GuruFocus
- 6 weeks ago - Axogen: Well Placed To Capitalize Growth At Higher Multiples - Seeking Alpha
- 2 months ago - Axogen Inc (AXGN) Shares Down 4.15% on Dec 27 - GuruFocus
- 3 months ago - Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® - GlobeNewsWire